The mechanism might be that empagliflozin decreases hepcidin, improves bone marrow hematopoiesis, mitochondrial function, and muscle energetics, and then improves LVEF and peak VO2, affecting the prognosis of heart failure patients.43, 44, 45. This evidence concerns the gene HAMP and heart failure.